Acticor Biotech SAS received PRIority Medicines status from the European Medicines Agency (EMA) for its drug candidate, glenzocimab, for the treatment of patients with stroke. Glenzocimab is currently being evaluated in the Phase 2/3 registration ACTISAVE study in stroke patients. This study started in Third Quarter 2021, with the inclusion of the first patient in Europe.

In parallel, ACTICOR had obtained an IND for this study from the U.S.Food and Drug Administration(FDA) in November 2021. To date, 87 patients have already been enrolled in Europe. A total of 1,000 patients will be included in the United States and Europe.

An interim futility analysis is planned after inclusion of the first 200 patients to confirm the baseline hypotheses.